Septerna, Inc. (SEPN) Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Septerna Inc NASDAQ:SEPN Healthcare · Biotechnology
AH Close $40.41 +0.00% vs close
AH Close $40.41 +0.00% vs close
All Press Release SEC Filings News
News
CRISPR Therapeutics (NASDAQ:CRSP) & Septerna (NASDAQ:SEPN) Head-To-Head Survey
defenseworld.net • 27d ago News
Analyzing Valneva (NASDAQ:VALN) and Septerna (NASDAQ:SEPN)
defenseworld.net • 1mo ago News
Comparing WAVE Life Sciences (NASDAQ:WVE) and Septerna (NASDAQ:SEPN)
defenseworld.net • 1mo ago Press Release
Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Septerna granted a non-qualified stock option to purchase 275,000 shares to Rajiv Patni, M.D., its newly appointed Chief Medical Officer, under the company's 2026 Inducement Plan.
The option carries a $37.37 exercise price, equal to the September 8, 2026 closing price, with a ten-year term and four-year vesting: 25% cliffs at the one-year anniversary and the remaining 75% vests monthly over 36 months.
The grant was made as an inducement material to Dr. Patni's employment under Nasdaq Listing Rule 5635(c)(4). Septerna is a clinical-stage biotech advancing oral small-molecule GPCR therapies via its Native Complex Platform in endocrinology, immunology, inflammation, and metabolic disease.
• 1mo ago AI analysis › Press Release
Septerna to Participate in Upcoming Investor Conferences
Septerna management will participate in two investor conferences during September 2026.
The company is scheduled for fireside chats at the Wells Fargo 21st Annual Healthcare Conference on September 8 and the Cantor Global Healthcare Conference on September 10.
Live webcasts of the presentations will be available on the company website and archived for 30 days.
• 1mo ago AI analysis › Press Release
Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer
Septerna appointed industry veteran Rajiv Patni, M.D., as Chief Medical Officer, bringing over 25 years of experience and a track record of 10 regulatory approvals to the clinical-stage biotech.
Dr. Patni joins from Judo Bio and previously served as Chief Research and Development Officer at Reata Pharmaceuticals, along with prior CMO roles at multiple acquired companies.
CEO Jeffrey Finer highlighted Patni's deep clinical development expertise as instrumental for advancing Septerna's pipeline of oral GPCR-targeting medicines.
• 2mo ago AI analysis › News
Septerna, Inc. (SEPN) Reports Q2 Loss, Beats Revenue Estimates
zacks.com • 2mo ago Press Release ● Major
Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results
Septerna reported Q2 2026 revenue of $26.7 million, driven by its collaboration with Novo Nordisk, and narrowed its net loss to $13.0 million compared to the prior year.
The company ended the quarter with $516.5 million in cash and marketable securities, providing a runway expected to fund operations into 2029.
Clinically, the Phase 1 trial for SEP-479 showed an elimination half-life of three to four days, supporting once-daily dosing, with SAD and MAD data now anticipated in Q1 2027.
• 2mo ago AI analysis › News
Septerna's Chief People Officer Sold Nearly 12,000 Company Shares. What Does That Mean for Investors?
fool.com • 3mo ago SEC Filing
SEPN: 8-K · proxy statement
Septerna, Inc. held its 2026 annual meeting of stockholders on June 26, 2026, where stockholders elected two Class II directors to three-year terms ending at the 2029 annual meeting.
Shalini Sharp, M.B.A. and Jake Simson, Ph.D. were each elected to the Board of Directors, receiving approximately 33.7 million votes in favor respectively, against roughly 5.8 million votes withheld for each nominee.
Stockholders also ratified the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026, with 41.2 million votes in favor and only 4,008 votes against.
SEC 8-K • 3mo ago News
Is Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares?
fool.com • 3mo ago Press Release
Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting
businesswire.com • 4mo ago Press Release ● Major ⚠ 1
Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results
Septerna reported positive Phase 1 data for SEP-631, supporting a Phase 2b trial in chronic spontaneous urticaria in the second half of 2026, and initiated a Phase 1 trial for SEP-479 in hypoparathyroidism.
The company posted Q1 revenue of $26.5 million, driven by the Novo Nordisk collaboration, compared to $0.2 million in the prior year.
Cash, cash equivalents, and marketable securities totaled $522.1 million, with a runway expected to extend into 2029.
• 5mo ago AI analysis › Press Release
Septerna to Present at Bank of America Securities Health Care Conference
Septerna announced that CEO Jeffrey Finer will present at the Bank of America Securities Health Care Conference in Las Vegas on May 12, 2026.
A live webcast will be available on the company's website and will be archived for at least 30 days following the event.
The company is a clinical-stage biotech focused on GPCR therapies using its proprietary Native Complex Platform.
• 5mo ago AI analysis › 
